| Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| ImmunoGen, Inc. | EVP R&D & MEDICAL AFFAIRS | Common Stock | 0 | $0 | $29.30 | Feb 12, 2024 | Direct |
| ImmunoGen, Inc. | EVP R&D & MEDICAL AFFAIRS | Restricted Stock Unit | 0 | $0 | $29.30 | Feb 12, 2024 | Direct |
| ImmunoGen, Inc. | EVP R&D & MEDICAL AFFAIRS | Stock Option (Right to Buy) | 0 | $0 | $4.56 | Feb 12, 2024 | Direct |
| Magenta Therapeutics, Inc. | Director | Stock Option (Right to Buy) | 40K | Aug 15, 2022 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
|---|---|---|---|---|---|---|---|
| IMGN | ImmunoGen, Inc. | Feb 12, 2024 | 3 | $0 | 4 | Feb 12, 2024 | EVP R&D & MEDICAL AFFAIRS |
| IMGN | ImmunoGen, Inc. | Feb 1, 2024 | 1 | $0 | 4 | Feb 5, 2024 | EVP R&D & MEDICAL AFFAIRS |
| IMGN | ImmunoGen, Inc. | Dec 29, 2023 | 1 | $21.2K | 4 | Jan 3, 2024 | EVP R&D & MEDICAL AFFAIRS |
| IMGN | ImmunoGen, Inc. | Dec 29, 2022 | 1 | $0 | 4 | Jan 3, 2023 | EVP R&D & MEDICAL AFFAIRS |
| IMGN | ImmunoGen, Inc. | Dec 29, 2022 | 0 | $0 | 3 | Jan 3, 2023 | EVP R&D & MEDICAL AFFAIRS |
| MGTA | Magenta Therapeutics, Inc. | Aug 15, 2022 | 1 | $0 | 4 | Aug 17, 2022 | Director |
| MGTA | Magenta Therapeutics, Inc. | Aug 15, 2022 | 0 | $0 | 3 | Aug 17, 2022 | Director |